Related Experiment Video
Updated: Aug 16, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
Published on: September 27, 2013
Delivery of antiangiogenic agents for cancer gene therapy
Paxton V Dickson1, Amit C Nathwani, Andrew M Davidoff
1Department of Surgery, St. Jude Children's Research Hospital, and the Department of Surgery, The University of Tennessee-Memphis, Health Science Center, TN 38163, USA.
Abstract:
The understanding that tumor growth and metastasis are angiogenesis dependent processes has led to interest in targeting tumor vasculature in anticancer therapy. Furthermore, recent insights into the molecular interactions that orchestrate physiologic and pathologic angiogenesis have resulted in a variety of antiangiogenic strategies. A gene therapy-mediated approach for the delivery of antiangiogenic agents has several advantages, including the potential for sustained expression. However, the choice of angiogenesis inhibitor, method of gene delivery, and target/site for transgene expression are important variables to be considered when designing this approach. Here we review the major alternatives within each of these categories and provide illustrative examples of their use in preclinical models.
Insights
Targeting tumor blood vessel growth (angiogenesis) is key for cancer therapy. Gene therapy offers sustained delivery of anti-angiogenic agents, with choices in inhibitors and delivery methods crucial for success.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Tumor growth and metastasis are dependent on angiogenesis.
- Targeting tumor vasculature is a promising anticancer strategy.
- Molecular insights have led to various antiangiogenic therapies.
Purpose of the Study:
- To review gene therapy-mediated antiangiogenic strategies.
- To discuss key variables in designing gene therapy approaches for cancer.
- To provide examples from preclinical models.
Main Methods:
- Review of antiangiogenic agents and gene delivery methods.
- Analysis of target/site selection for transgene expression.
- Illustrative examples from preclinical studies.
Main Results:
- Gene therapy offers sustained expression of antiangiogenic agents.
- Several antiangiogenic strategies and gene delivery methods are available.
- Preclinical models demonstrate the potential of these approaches.
Conclusions:
- Gene therapy is a viable approach for delivering antiangiogenic agents.
- Careful consideration of inhibitor, delivery method, and target site is essential.
- Further preclinical research is warranted to optimize these strategies.
More Related Videos
13:58A Rabbit Model of Durable Transgene Expression in Jugular Vein to Common Carotid Artery Interposition Grafts
Published on: September 10, 2018
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Related Concept Videos
Gene Therapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy